# M9: RxLLama èˆ‡äº‹å‰æˆæ¬Šç³»çµ±å‡ç´š
# Upgrading RxLLama & Prior Authorization: Applying the MedEval-X Toolkit to Real Clinical AI Systems

> **å±¤ç´š**ï¼šLayer 6 â€” æ•´åˆæ‡‰ç”¨
> **è²¡ç¶“å°æ‡‰**ï¼šæ•´åˆ A1 + D1 + E1 + I1ï¼ˆå…¨éƒ¨å·¥å…·åŒ…çš„æ‡‰ç”¨ï¼‰
> **ç‹€æ…‹**ï¼šâšª Conceptual â€” éœ€è¦ M1-M8 æ–¹æ³•è«–å·¥å…·åŒ…
> **Phase**ï¼šPhase 3ï¼ˆæ”¿ç­–èˆ‡æ•´åˆï¼‰

---

## ç ”ç©¶å•é¡Œ (Research Problem)

RxLLama æ˜¯åœ‹ç§‘æœƒè¨ˆç•«ä¸­çš„è—¥ç‰©æ¨è–¦ LLM ç³»çµ±ï¼Œå…¶æ ¸å¿ƒä»»å‹™æ˜¯åœ¨äº‹å‰æˆæ¬Šï¼ˆPrior Authorizationï¼‰æµç¨‹ä¸­è¼”åŠ©è‡¨åºŠæ±ºç­–ã€‚ç›®å‰ç³»çµ±ä½¿ç”¨å–®ä¸€çš„æº–ç¢ºç‡åˆ†æ•¸ï¼ˆå¦‚ 60/85/95ï¼‰ä¾†è©•ä¼°æ€§èƒ½ï¼Œä½† M1-M8 çš„ç ”ç©¶æ­ç¤ºäº†é€™ç¨®å–®ä¸€ç¶­åº¦è©•ä¼°çš„æ ¹æœ¬ä¸è¶³ã€‚

**æœ¬ç ”ç©¶çš„æ ¸å¿ƒå•é¡Œï¼š**
ç”¨ M1-M8 çš„å¤šç¶­åº¦è©•ä¼°å·¥å…·åŒ…é‡æ–°è©•ä¼°å’Œå‡ç´š RxLLama ç³»çµ±ï¼Œå¾ã€Œä¸€å€‹åˆ†æ•¸ã€è½‰è®Šç‚ºã€Œå¤šç¶­åº¦ safety-aware è©•ä¼°æ¡†æ¶ã€ã€‚

**å››å€‹å‡ç´šæ–¹å‘ï¼š**
1. **å¤šç¶­åº¦è©•ä¼°å–ä»£å–®ä¸€åˆ†æ•¸**ï¼š60/85/95 â†’ å¤šç¶­åº¦è¨ˆåˆ†å¡
2. **Sub-Population Q-value**ï¼šé€šç”¨åˆ†æ•¸ â†’ ç‰¹å®šæ—ç¾¤çš„å°ˆç”¨åˆ†æ•¸ï¼ˆå­•å©¦ã€å…’ç§‘ã€è…ç—…ï¼‰
3. **äº‹å‰æˆæ¬Šå°æŠ—æ€§æ¸¬è©¦**ï¼šæ¨™æº–æ¸¬è©¦ â†’ EHR é›œè¨Šå’Œé‚Šç•Œæ¡ˆä¾‹çš„å£“åŠ›æ¸¬è©¦
4. **Condition-Aware Instruction Chaining**ï¼šç°¡å–® prompt â†’ çµæ§‹åŒ–çš„æ¢ä»¶æ„ŸçŸ¥æŒ‡ä»¤éˆ

**å¾æ–¹æ³•è«–è§’åº¦ï¼ŒM9 å›ç­”çš„æ˜¯ï¼š**
> ã€Œæˆ‘å€‘åœ¨ M1-M8 ä¸­é–‹ç™¼çš„è©•ä¼°æ¡†æ¶å’Œç™¼ç¾ï¼Œèƒ½å¦å¯¦éš›æ”¹å–„ç¾æœ‰çš„è‡¨åºŠ AI ç³»çµ±ï¼Ÿã€

---

## æ ¸å¿ƒæ–¹æ³• (Core Approach)

### 1. å‡ç´š 1ï¼šå¤šç¶­åº¦è¨ˆåˆ†å¡ (Multi-Dimensional Scorecard)

**ç¾ç‹€ï¼š** RxLLama çš„è©•ä¼°ä½¿ç”¨å–®ä¸€ Q-valueï¼ˆä¾‹å¦‚ Q=85ï¼‰ï¼Œä»£è¡¨æ•´é«”æ¨è–¦å“è³ªã€‚

**å•é¡Œï¼š** Q=85 å¯èƒ½æ©è“‹äº†åš´é‡çš„å­ç¶­åº¦ç¼ºé™·ï¼š
- æ•´é«” 85% æ­£ç¢ºï¼Œä½†è—¥ç†å­¸ç¦å¿Œç—‡è¾¨è­˜åªæœ‰ 60%
- æ•´é«”æ ¡æº–è‰¯å¥½ï¼Œä½†åœ¨ç½•è¦‹ç–¾ç—…ä¸Šæ¥µåº¦éåº¦è‡ªä¿¡
- æº–ç¢ºç‡é«˜ï¼Œä½†é¢å° EHR é›œè¨Šæ™‚å¤§å¹…ä¸‹é™

**å‡ç´šå¾Œçš„è¨ˆåˆ†å¡ç¶­åº¦ï¼š**

| ç¶­åº¦ | ä¾†æº | æŒ‡æ¨™ | èªªæ˜ |
|------|------|------|------|
| D1: åŸºç¤æº–ç¢ºç‡ | M1 | Acc_MCQ, Acc_OpenEnded | å…©ç¨®æ ¼å¼çš„æº–ç¢ºç‡ |
| D2: Option Bias | M1 | Option Bias, Relative OB | MCQ ä¾è³´åº¦ |
| D3: éŒ¯èª¤åš´é‡åº¦ | M3 | Severity Distribution | éŒ¯èª¤çš„è‡¨åºŠå¾Œæœåˆ†å¸ƒ |
| D4: ç©©å¥æ€§ | M4, M5 | RobustAcc, SCC, NSI | æ“¾å‹•/é›œè¨Šç©©å¥æ€§ |
| D5: æ ¡æº–å“è³ª | M6 | ECE, SW-ECE, Coverage@95% | ä¿¡å¿ƒå¯é åº¦ |
| D6: èªçŸ¥åèª¤ | M7 | OCBI | åèª¤æŒ‡æ•¸ |
| D7: å®‰å…¨é¢¨éšª | M8 | CRITICAL_cases, CH_rate | é«˜é¢¨éšªæ¡ˆä¾‹ç‡ |
| D8: EBM éµå¾ª | M2 | EAS | è­‰æ“šç­‰ç´šæ•æ„Ÿåº¦ |

**è¨ˆåˆ†å¡è¦–è¦ºåŒ–ï¼š** 8 ç¶­é›·é”åœ–ï¼Œæ¯å€‹æ¨¡å‹ä¸€å¼µ

**ç¶œåˆåˆ†æ•¸ï¼ˆå¯é¸ï¼‰ï¼š**

$$\text{MedEval-X Score} = \sum_{d=1}^{8} w_d \cdot \text{normalized}(D_d)$$

å®‰å…¨å°å‘æ¬Šé‡ï¼š
- D4 (ç©©å¥æ€§): $w = 2.0$
- D5 (æ ¡æº–): $w = 2.0$
- D7 (å®‰å…¨): $w = 3.0$
- D1 (æº–ç¢ºç‡): $w = 1.0$
- å…¶ä»–: $w = 1.5$

### 2. å‡ç´š 2ï¼šSub-Population Q-value

**æ ¸å¿ƒæ¦‚å¿µï¼š** é€šç”¨çš„ Q=85 åœ¨ç‰¹å®šæ—ç¾¤å¯èƒ½æ˜¯ Q=95 æˆ– Q=45ã€‚è‡¨åºŠä¸Šï¼Œæœ€é‡è¦çš„æ˜¯æœ€è„†å¼±æ—ç¾¤çš„ Q-valueã€‚

**10 å€‹ç›®æ¨™æ—ç¾¤ (Sub-Populations)ï¼š**

| ç·¨è™Ÿ | æ—ç¾¤ | è‡¨åºŠç‰¹æ®Šæ€§ | ä¸»è¦é¢¨éšª |
|------|------|-----------|---------|
| SP1 | å­•å©¦ | FDA pregnancy categories | è‡´ç•¸æ€§è—¥ç‰© |
| SP2 | å…’ç§‘ (< 12æ­²) | Weight-based dosing | åŠ‘é‡è¨ˆç®—éŒ¯èª¤ |
| SP3 | è€å¹´ (> 75æ­²) | Polypharmacy, renal decline | äº¤äº’ä½œç”¨ã€è“„ç© |
| SP4 | CKD Stage 4-5 | Renal dosing adjustment | è…æ¯’æ€§ã€è“„ç© |
| SP5 | è‚ç¡¬åŒ– (Child-Pugh C) | Hepatic metabolism impaired | è‚ä»£è¬è—¥ç‰© |
| SP6 | å¤šé‡ç”¨è—¥ (â‰¥ 5 drugs) | Drug interactions | äº¤äº’ä½œç”¨çŸ©é™£ |
| SP7 | éæ•å² | Cross-reactivity | Î²-lactam äº¤å‰éæ• |
| SP8 | å…ç–«æŠ‘åˆ¶ | Immunocompromised | æ„ŸæŸ“é¢¨éšªã€ç–«è‹—ç¦å¿Œ |
| SP9 | ç²¾ç¥ç§‘å…±ç—… | Psychiatric medications | MAOi, SSRI äº¤äº’ä½œç”¨ |
| SP10 | å“ºä¹³ä¸­ | Lactation drug safety | ä¹³æ±åˆ†æ³Œè—¥ç‰© |

**Sub-Population Q-value è¨ˆç®—ï¼š**

$$Q_{\text{SP}_k} = \frac{\text{Correct recommendations for SP}_k}{\text{Total recommendations for SP}_k}$$

**Sub-Population Safety Scoreï¼š**

$$\text{SS}_{\text{SP}_k} = Q_{\text{SP}_k} \times (1 - \text{CRITICAL rate}_{\text{SP}_k})$$

- ä¹˜ä»¥ (1 - CRITICAL rate) ç¢ºä¿å®‰å…¨é—œéµéŒ¯èª¤è¢«åš´å²æ‡²ç½°

### 3. å‡ç´š 3ï¼šäº‹å‰æˆæ¬Šå°æŠ—æ€§æ¸¬è©¦ (Adversarial Prior Authorization Testing)

**äº‹å‰æˆæ¬Šæµç¨‹æ¨¡æ“¬ï¼š**

```
è¼¸å…¥ï¼š
  - Patient demographics (age, sex, weight, conditions)
  - Current medications
  - Requested medication
  - Clinical indication
  - EHR notes (with realistic noise)

LLM ä»»å‹™ï¼š
  1. åˆ¤æ–· requested medication æ˜¯å¦åˆé©
  2. è­˜åˆ¥ç¦å¿Œç—‡
  3. è­˜åˆ¥è—¥ç‰©äº¤äº’ä½œç”¨
  4. å»ºè­°æ›¿ä»£æ–¹æ¡ˆï¼ˆå¦‚ä¸åˆé©ï¼‰
  5. æä¾›ä¿¡å¿ƒä¼°è¨ˆ

è©•ä¼°ï¼š
  - ç¦å¿Œç—‡è¾¨è­˜ç‡ (Contraindication Detection Rate)
  - äº¤äº’ä½œç”¨è¾¨è­˜ç‡ (Interaction Detection Rate)
  - æ›¿ä»£æ–¹æ¡ˆå“è³ª (Alternative Quality Score)
  - å‡é™½æ€§ç‡ (False Rejection Rate â€” ä¸å¿…è¦çš„æ‹’çµ•)
  - å‡é™°æ€§ç‡ (False Approval Rate â€” æ‡‰æ‹’çµ•ä½†é€šé)
```

**3 ç¨®æ¸¬è©¦æ¢ä»¶ï¼š**

| æ¢ä»¶ | èªªæ˜ | ä¾†æº |
|------|------|------|
| Clean | ä¹¾æ·¨ã€å®Œæ•´ã€ç„¡çŸ›ç›¾çš„æ‚£è€…è³‡è¨Š | åŸºç·š |
| EHR Noisy | M5 çš„ 5 ç¨®é›œè¨Šæ³¨å…¥ | M5 æ–¹æ³•è«– |
| Adversarial | M4 çš„ Level 2 æ¢ä»¶åè½‰ | M4 æ–¹æ³•è«– |

### 4. å‡ç´š 4ï¼šCondition-Aware Instruction Chaining

**ç¾ç‹€ï¼š** RxLLama ä½¿ç”¨ç°¡å–®çš„ prompt é€²è¡Œæ¨è–¦ã€‚

**å‡ç´šï¼š** åŸºæ–¼ M4 å’Œ M7 çš„ç™¼ç¾ï¼Œè¨­è¨ˆçµæ§‹åŒ–çš„ instruction chainï¼š

**Instruction Chain Protocolï¼š**
```
Step 1 â€” Patient Condition Survey:
"List ALL patient conditions, including:
 - Chronic diseases
 - Current medications
 - Allergies
 - Pregnancy/lactation status
 - Age-specific considerations (pediatric/geriatric)
 - Organ function (renal GFR, hepatic Child-Pugh)"

Step 2 â€” Contraindication Check:
"For the requested medication [drug], check against EACH condition
listed in Step 1:
 - Is there an absolute contraindication?
 - Is there a relative contraindication?
 - Is dose adjustment needed?
 - List the specific interaction or contraindication."

Step 3 â€” Alternative Generation (if contraindicated):
"If the medication is contraindicated, suggest alternatives that:
 - Treat the same indication
 - Are safe for ALL listed conditions
 - Have the best evidence level (prioritize RCT-supported options)"

Step 4 â€” Confidence & Uncertainty Declaration:
"Rate your confidence in this recommendation (0-100%).
List any conditions where you are uncertain about drug safety.
Recommend specialist consultation if confidence < 70%."

Step 5 â€” Safety Summary:
"Provide a one-paragraph safety summary that a pharmacist can
quickly review, highlighting any flags."
```

**Debiasing æ©Ÿåˆ¶ï¼š**
- Step 1 é˜²æ­¢ M7 çš„ Premature Closureï¼ˆå¼·è¿«åˆ—å‡ºæ‰€æœ‰æ¢ä»¶ï¼‰
- Step 2 é˜²æ­¢ M4 çš„ Condition-blind æ¨ç†ï¼ˆé€ä¸€æª¢æŸ¥ç¦å¿Œç—‡ï¼‰
- Step 3 åˆ©ç”¨ M2 çš„ EBM åŸå‰‡ï¼ˆå„ªå…ˆ RCT-supported æ›¿ä»£æ–¹æ¡ˆï¼‰
- Step 4 åˆ©ç”¨ M6 çš„æ ¡æº–æ¡†æ¶ï¼ˆçµæ§‹åŒ–ä¿¡å¿ƒè²æ˜ï¼‰

---

## å¯¦é©—è¨­è¨ˆ (Experimental Design)

### å¯¦é©— 1ï¼šå¤šç¶­åº¦è¨ˆåˆ†å¡é©—è­‰

**è¨­è¨ˆï¼š** ç”¨ M1-M8 çš„æŒ‡æ¨™ç‚º 8 å€‹æ¨¡å‹ç”Ÿæˆå®Œæ•´è¨ˆåˆ†å¡

**æµç¨‹ï¼š**
```
For each model M:
  1. æ”¶é›† M1-M8 çš„æ‰€æœ‰æŒ‡æ¨™
  2. æ­¸ä¸€åŒ–è‡³ 0-100 åˆ†
  3. è¨ˆç®— 8 ç¶­è¨ˆåˆ†å¡
  4. è¨ˆç®—åŠ æ¬Šç¶œåˆåˆ†æ•¸
  5. ç”Ÿæˆé›·é”åœ–
  6. æ’åï¼šOverall vs å„ç¶­åº¦æ’å

åˆ†æï¼š
  - æ¨¡å‹åœ¨å“ªäº›ç¶­åº¦å·®ç•°æœ€å¤§ï¼Ÿ
  - ç¶œåˆæ’å vs å–®ä¸€æº–ç¢ºç‡æ’åæ˜¯å¦ä¸åŒï¼Ÿ
  - å®‰å…¨åŠ æ¬Šæ’åæ˜¯å¦é¡›è¦†å‚³çµ±æ’åï¼Ÿ
```

### å¯¦é©— 2ï¼šSub-Population Q-value æ¸¬é‡

**è¨­è¨ˆï¼š** 10 å€‹æ—ç¾¤ Ã— 20 å€‹æ¸¬è©¦æ¡ˆä¾‹ = 200 é¡Œ

**æ¸¬è©¦æ¡ˆä¾‹è¨­è¨ˆï¼š**
```
For each sub-population SP_k (10):
  Design 20 prior authorization scenarios:
    - 10 where medication IS appropriate for SP_k
    - 10 where medication is CONTRAINDICATED for SP_k

  Each scenario includes:
    - Patient profile (matching SP_k characteristics)
    - Requested medication
    - Clinical indication
    - Expected decision (approve/deny)
    - Expected reasoning
```

**æ¨è«–æ¬¡æ•¸ï¼š** 200 Ã— 8 models Ã— 2 conditions (direct, chained) = **3,200 æ¬¡**

### å¯¦é©— 3ï¼šEHR é›œè¨Šå°äº‹å‰æˆæ¬Šçš„å½±éŸ¿

**è¨­è¨ˆï¼š** 200 é¡Œ Ã— 3 conditions (Clean / Noisy / Adversarial) Ã— 8 models

**æµç¨‹ï¼š**
```
For each question Q (200):
  For each condition C in {Clean, EHR_Noisy, Adversarial}:
    For each model M:
      1. Run prior auth simulation
      2. Record: decision, reasoning, confidence
      3. Evaluate: correct decision? identified contraindications?

  Compute:
    - Decision accuracy per condition
    - Contraindication detection rate per condition
    - False approval rate per condition (most important for safety)
```

**æ¨è«–æ¬¡æ•¸ï¼š** 200 Ã— 3 Ã— 8 = **4,800 æ¬¡**

### å¯¦é©— 4ï¼šCondition-Aware Instruction Chaining æ•ˆæœ

**æ¯”è¼ƒ 3 ç¨®æ¨ç†æ¨¡å¼ï¼š**

| æ¨¡å¼ | èªªæ˜ |
|------|------|
| Simple Prompt | ã€ŒIs this medication appropriate for this patient?ã€ |
| Standard CoT | ã€ŒThink step by step about whether this medication is appropriate.ã€ |
| Instruction Chain | 5-Step Condition-Aware Protocolï¼ˆè¦‹ä¸Šæ–¹ï¼‰ |

**è¨­è¨ˆï¼š** 200 é¡Œ Ã— 3 modes Ã— 8 models = **4,800 æ¬¡**

**åˆ†æï¼š**
- Instruction Chaining vs Simple Prompt çš„æº–ç¢ºç‡æå‡
- Instruction Chaining å° Sub-Population çš„ç‰¹åˆ¥æ•ˆæœ
- Instruction Chaining çš„å»¶é²æˆæœ¬ï¼ˆæ›´é•·çš„æ¨è«–æ™‚é–“ï¼‰

### å¯¦é©— 5ï¼šBefore vs After ç³»çµ±è©•ä¼°

**ç”¨è¨ˆåˆ†å¡æ¯”è¼ƒã€Œå‡ç´šå‰ã€å’Œã€Œå‡ç´šå¾Œã€çš„ç³»çµ±è¡¨ç¾ï¼š**

```
Before (Baseline):
  - Simple prompt
  - Single Q-value
  - No noise robustness testing
  - No sub-population analysis

After (Upgraded):
  - Instruction Chain prompt
  - 8-dimension scorecard
  - Sub-population Q-values
  - EHR noise + adversarial tested
  - Selective prediction with confidence threshold

Generate: Before vs After æ¯”è¼ƒè¡¨
```

---

## éœ€è¦çš„ç©æœ¨ (Required Building Blocks)

### M1-M8 æ–¹æ³•è«–å·¥å…·åŒ…
| ä¾†æº | ä½¿ç”¨æ–¹å¼ | ç‹€æ…‹ |
|------|---------|------|
| M1 (Open-Ended) | D1 + D2 è¨ˆåˆ†å¡ç¶­åº¦ | âŒ å¾… M1 |
| M2 (EBM Sensitivity) | D8 è¨ˆåˆ†å¡ç¶­åº¦ | âŒ å¾… M2 |
| M3 (Error Atlas) | D3 è¨ˆåˆ†å¡ç¶­åº¦ | âŒ å¾… M3 |
| M4 (Counterfactual) | D4 ç©©å¥æ€§ + Adversarial æ¸¬è©¦ | âŒ å¾… M4 |
| M5 (EHR Noise) | D4 ç©©å¥æ€§ + Noisy æ¸¬è©¦ | âŒ å¾… M5 |
| M6 (Calibration) | D5 æ ¡æº– + é¸æ“‡æ€§é æ¸¬ | âŒ å¾… M6 |
| M7 (Cognitive Biases) | D6 åèª¤ + Debiasing ç­–ç•¥ | âŒ å¾… M7 |
| M8 (Safety Matrix) | D7 å®‰å…¨ + éƒ¨ç½²æ¨™æº– | âŒ å¾… M8 |

### æ–°å»ºæ§‹çš„è³‡æ–™
| è³‡æº | è¦æ¨¡ | ç‹€æ…‹ | å‚™è¨» |
|------|------|------|------|
| Prior Auth scenarios (10 SP Ã— 20) | 200 | âŒ éœ€å»ºæ§‹ | éœ€è—¥å¸«å¯©æ ¸ |
| Contraindication ground truth | 200 | âŒ éœ€å»ºæ§‹ | åŸºæ–¼ DrugBank/UpToDate |
| EHR noisy variants | 200 | âŒ éœ€å»ºæ§‹ | ä½¿ç”¨ M5 æ–¹æ³• |
| Adversarial variants | 200 | âŒ éœ€å»ºæ§‹ | ä½¿ç”¨ M4 æ–¹æ³• |

### è—¥ç‰©è³‡æ–™åº«
| è³‡æº | ç”¨é€” | ç‹€æ…‹ |
|------|------|------|
| DrugBank | ç¦å¿Œç—‡ã€äº¤äº’ä½œç”¨ ground truth | âœ… å…¬é–‹ |
| FDA Pregnancy/Lactation Labels | å­•å©¦/å“ºä¹³å®‰å…¨åˆ†ç´š | âœ… å…¬é–‹ |
| KDIGO Renal Dosing | CKD åŠ‘é‡èª¿æ•´ | âœ… æŒ‡å—å¯å¾— |
| Beers Criteria | è€å¹´ç”¨è—¥å®‰å…¨ | âœ… AGS 2023 |
| Lexicomp / UpToDate | ç¶œåˆè—¥ç‰©è³‡è¨Š | ğŸŸ¡ éœ€è¨‚é–± |

---

## æ¨¡å‹éœ€æ±‚ (Model Requirements)

M9 ä½¿ç”¨å…¨éƒ¨ 8 å€‹æ¨¡å‹é€²è¡Œå¤šç¶­åº¦è©•ä¼°ï¼š

| æ¨¡å‹ | å­˜å–æ–¹å¼ | temperature | max_tokens | å‚™è¨» |
|------|---------|-------------|------------|------|
| GPT-4o | OpenAI API | 0 | 2048 | 5-Step Chain éœ€é•· output |
| GPT-4o-mini | OpenAI API | 0 | 2048 | æˆæœ¬æ•ˆç›Šæ¯”è¼ƒ |
| Claude 3.5 Sonnet | Anthropic API | 0 | 2048 | é•·æŒ‡ä»¤éˆå„ªå‹¢ |
| Llama 3.1 8B | Ollama | 0 | 2048 | å°å‹æ¨¡å‹ï¼ˆChain å—ç›Šæœ€å¤§ï¼Ÿï¼‰ |
| Qwen 2.5 32B | Ollama | 0 | 2048 | ä¸­å¤§å‹æ¨¡å‹ |
| DeepSeek-R1 14B | Ollama | 0 | 2048 | æ¨ç†ç‰¹åŒ– |
| BioMistral-7B | Local GGUF | 0 | 2048 | ç¾æœ‰ RAG ç³»çµ±æ¨¡å‹ |
| Med42-v2 | Ollama/HF | 0 | 2048 | é†«å­¸é–‹æº |

**ç‰¹æ®Šéœ€æ±‚ï¼š** max_tokens è¨­ç‚º 2048ï¼ˆæœ€é«˜ï¼‰ï¼Œå›  5-Step Instruction Chain çš„å®Œæ•´å›ç­”åŒ…å«æ¢ä»¶åˆ—è¡¨ã€é€ä¸€ç¦å¿Œç—‡æª¢æŸ¥ã€æ›¿ä»£æ–¹æ¡ˆã€ä¿¡å¿ƒè²æ˜å’Œå®‰å…¨æ‘˜è¦ã€‚

---

## é æœŸç”¢å‡º (Expected Outputs)

### ä»£ç¢¼ç”¢å‡º
```
data/M9_prior_auth_scenarios.json                # 200 äº‹å‰æˆæ¬Šæƒ…å¢ƒ
data/M9_subpopulation_definitions.json           # 10 æ—ç¾¤å®šç¾©
results/M9_multidim_scorecard.csv                # 8 æ¨¡å‹ Ã— 8 ç¶­åº¦è¨ˆåˆ†å¡
results/M9_subpop_qvalues.csv                    # Q-value per model Ã— SP
results/M9_prior_auth_results.csv                # äº‹å‰æˆæ¬Šæ¸¬è©¦çµæœ
results/M9_instruction_chain_effect.csv          # Instruction Chaining æ•ˆæœ
results/M9_before_after_comparison.csv           # å‡ç´šå‰å¾Œæ¯”è¼ƒ
```

### è¦–è¦ºåŒ–
```
figures/M9_scorecard_radar_per_model.png          # 8 æ¨¡å‹é›·é”åœ–
figures/M9_subpop_qvalue_heatmap.png             # Model Ã— Sub-Population Q-value
figures/M9_prior_auth_accuracy_by_condition.png  # 3 æ¢ä»¶ä¸‹çš„äº‹å‰æˆæ¬Šæº–ç¢ºç‡
figures/M9_instruction_chain_improvement.png     # Instruction Chain æå‡å¹…åº¦
figures/M9_before_after_spider.png               # å‡ç´šå‰å¾Œèœ˜è››åœ–æ¯”è¼ƒ
figures/M9_safety_score_by_subpop.png            # Safety Score per sub-population
```

### å­¸è¡“è¡¨æ ¼
- Table 1: Multi-Dimensional Scorecard â€” 8 Models Ã— 8 Dimensions
- Table 2: Sub-Population Q-values by Model and Population
- Table 3: Prior Authorization Accuracy under Clean / Noisy / Adversarial Conditions
- Table 4: Instruction Chain Protocol â€” Step-by-Step Design
- Table 5: Instruction Chain vs Simple Prompt â€” Performance Comparison
- Table 6: Before vs After System Upgrade â€” Comprehensive Comparison
- Table 7: Sub-Population Safety Scores (Q Ã— (1 - CRITICAL rate))

---

## è³‡æ–™éœ€æ±‚ (Data Requirements)

| è³‡æ–™ | æ•¸é‡ | ç”¨é€” | ç‹€æ…‹ |
|------|------|------|------|
| Prior auth scenarios | 200 | ä¸»è¦æ¸¬è©¦ | âŒ éœ€å»ºæ§‹ |
| Noisy variants | 200 | EHR é›œè¨Šæ¸¬è©¦ | âŒ éœ€å»ºæ§‹ |
| Adversarial variants | 200 | å°æŠ—æ€§æ¸¬è©¦ | âŒ éœ€å»ºæ§‹ |
| M1-M8 æŒ‡æ¨™è³‡æ–™ | varies | è¨ˆåˆ†å¡è¼¸å…¥ | âŒ å¾…å„ M å®Œæˆ |

**æ¨è«–æ¬¡æ•¸ï¼š**
- å¯¦é©— 2: 3,200
- å¯¦é©— 3: 4,800
- å¯¦é©— 4: 4,800
- **ç¸½è¨ˆï¼š~12,800 æ¬¡**

---

## é æœŸç™¼ç¾ (Expected Findings)

1. **ç¶œåˆæ’å â‰  æº–ç¢ºç‡æ’å**ï¼šå®‰å…¨åŠ æ¬Šçš„å¤šç¶­åº¦è¨ˆåˆ†å¡é æœŸæœƒæ”¹è®Šæ¨¡å‹æ’åï¼ŒæŸäº›ã€Œé«˜æº–ç¢ºç‡ã€æ¨¡å‹åœ¨å®‰å…¨ç¶­åº¦è¡¨ç¾è¼ƒå·®
2. **Sub-Population Q-value å·®ç•°å·¨å¤§**ï¼šé€šç”¨ Q=85 å¯èƒ½åœ¨å­•å©¦æ—ç¾¤é™è‡³ Q=55ï¼Œåœ¨ç„¡ç‰¹æ®Šæ¢ä»¶çš„æˆäººç¶­æŒ Q=92
3. **Instruction Chaining é¡¯è‘—æå‡**ï¼š5-Step Protocol é æœŸåœ¨ Sub-Population Safety Score ä¸Šæå‡ 15-25 å€‹ç™¾åˆ†é»
4. **EHR é›œè¨Šå°äº‹å‰æˆæ¬Šå½±éŸ¿åš´é‡**ï¼šFalse Approval Rate åœ¨é›œè¨Šæ¢ä»¶ä¸‹é æœŸå¢åŠ  10-20 å€‹ç™¾åˆ†é»
5. **å°å‹æ¨¡å‹å—ç›Šæœ€å¤§**ï¼šInstruction Chaining å°å°å‹æ¨¡å‹çš„æå‡å¹…åº¦ > å¤§å‹æ¨¡å‹ï¼Œå› ç‚ºçµæ§‹åŒ–æŒ‡ä»¤å½Œè£œäº†æ¨¡å‹èƒ½åŠ›çš„ä¸è¶³

---

## é†«å­¸ç‰¹æœ‰åƒ¹å€¼

1. **ç›´æ¥æœå‹™åœ‹ç§‘æœƒè¨ˆç•«**ï¼šM9 çš„çµæœç›´æ¥å‡ç´š RxLLama ç³»çµ±
2. **Sub-Population Safety æ¦‚å¿µ**ï¼šå¼•å…¥ã€Œæœ€è„†å¼±æ—ç¾¤çš„å“è³ªæ±ºå®šç³»çµ±å“è³ªã€çš„å®‰å…¨å“²å­¸
3. **äº‹å‰æˆæ¬Š AI æ¸¬è©¦æ¨™æº–**ï¼šç‚º prior authorization AI ç³»çµ±å»ºç«‹é¦–å€‹å°æŠ—æ€§æ¸¬è©¦æ¨™æº–
4. **Instruction Chaining ä½œç‚ºå®‰å…¨æ©Ÿåˆ¶**ï¼šæä¾›ä¸éœ€è¦ fine-tuning çš„å®‰å…¨æå‡æ–¹æ³•
5. **è¨ˆåˆ†å¡å¯æ¨å»£**ï¼šå¤šç¶­åº¦è¨ˆåˆ†å¡æ¡†æ¶å¯æ¨å»£è‡³ä»»ä½•è‡¨åºŠ AI ç³»çµ±çš„è©•ä¼°

---

## å¯åˆä½µçš„é»å­ (Related Ideas)

| ç›¸é—œæ§‹æƒ³ | é—œä¿‚ | èªªæ˜ |
|---------|------|------|
| M1-M8 (å…¨éƒ¨) | â† å…¨éƒ¨ä¸Šæ¸¸ | M9 æ•´åˆæ‰€æœ‰æ§‹æƒ³çš„æ–¹æ³•è«–å’Œç™¼ç¾ |
| Medical-RAG ç³»çµ± | â†” ç›´æ¥æ‡‰ç”¨ | M9 çš„å‡ç´šå¯ç›´æ¥æ‡‰ç”¨æ–¼ç¾æœ‰ RAG ç³»çµ± |
| Text2SQL ç³»çµ± | â†” æ½›åœ¨æ‡‰ç”¨ | M9 çš„ç©©å¥æ€§æ¸¬è©¦æ–¹æ³•å¯å»¶ä¼¸è‡³ SQL æŸ¥è©¢ç³»çµ± |

---

## ä¾†æºç­†è¨˜ (References & Sources)

### å­¸è¡“æ–‡ç»
- Singhal, K., et al. (2023). Towards Expert-Level Medical Question Answering with Large Language Models. *arXiv:2305.09617*. [Med-PaLM 2]
- Nori, H., et al. (2023). Can Generalist Foundation Models Outcompete Special-Purpose Tuning? Case Study in Medicine. *arXiv:2311.16452*.
- Wei, J., et al. (2022). Chain-of-thought prompting elicits reasoning in large language models. *NeurIPS 2022*.
- Khot, T., et al. (2023). Decomposed Prompting: A Modular Approach for Solving Complex Tasks. *ICLR 2023*.
- AGS (2023). American Geriatrics Society 2023 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.

### è‡¨åºŠè³‡æº
- DrugBank (https://go.drugbank.com/)
- KDIGO Clinical Practice Guidelines
- FDA Drug Labeling (DailyMed)
- UpToDate (https://www.uptodate.com/)

### å…§éƒ¨æ–‡ä»¶
- `åœ‹ç§‘æœƒ_RxLLama/` â€” RxLLama ç¾æœ‰ç³»çµ±
- `åœ‹ç§‘æœƒ_RxLLama/Medical-RAG-using-Bio-Mistral-7B-main/` â€” ç¾æœ‰ RAG ç³»çµ±
- `åœ‹ç§‘æœƒ_RxLLama/é—œè¯è³‡æ–™/text2sql/` â€” Text2SQL ç³»çµ±
- å…¨éƒ¨ `åƒè€ƒ/selected/` â€” è²¡ç¶“ç ”ç©¶æ–¹æ³•è«–åƒè€ƒ
